SCHEMBL5337684

SCHEMBL5337684

CC(C)(C)OC(=O)N1CCCCC1CNc1cccc(N)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.53
KDM1A O60341 1/20 0.49
PDE8B O95263 1/20 0.46
OPRD1 P41143 1/20 0.44
ALOX5AP P20292 1/20 0.43
FEN1 P39748 1/20 0.43
TRPV1 Q8NER1 1/20 0.43
METTL3 Q86U44 1/20 0.42
CHEK2 O96017 1/20 0.41
PDE7B Q9NP56 1/20 0.41
FPR3 P25089 1/20 0.41
FPR2 P25090 1/20 0.41
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
TSHR P16473 1/20 0.40
PARP1 P09874 1/20 0.40
CPT2 P23786 1/20 0.39
CPT1A P50416 1/20 0.39
SCN5A Q14524 1/20 0.39
SCN3A Q9NY46 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19141219 0.85 PRMT5 (0.53) PRMT5KDM1APDE8BOPRD1ALOX5AP
SCHEMBL16333400 0.83 KDM1A (0.49) PRMT5KDM1APDE8BOPRD1ALOX5AP
SCHEMBL31437092 0.81 KDM1A (0.52) PRMT5KDM1APDE8BOPRD1TRPV1
SCHEMBL15984993 0.81 PRMT5 (0.49) PRMT5KDM1APDE8BOPRD1TRPV1
SCHEMBL28332575 0.81 KDM1A (0.52) PRMT5KDM1APDE8BOPRD1TRPV1
SCHEMBL12311356 0.79 OPRD1 (0.53) PRMT5KDM1AOPRD1FPR3FPR2
SCHEMBL16845683 0.79 PRMT5 (0.46) PRMT5KDM1AOPRD1ALDH1A1LMNA
SCHEMBL15891825 0.78 ALDH1A1 (0.52) PRMT5KDM1AOPRD1ALOX5APFEN1
SCHEMBL15056678 0.78 PRMT5 (0.49) PRMT5KDM1AOPRD1TRPV1PDE7B
SCHEMBL15056676 0.78 PRMT5 (0.49) PRMT5KDM1AOPRD1TRPV1PDE7B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7196104-B2 Thiazolyl urea compounds and methods of uses AMGEN, INC. (US) 2007-03-27 US disclosed
EP-1483263-A1 THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER Amgen Inc. (US) 2004-12-08 EP disclosed
US-20040044044-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2004-03-04 US disclosed
US-20040039029-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2004-02-26 US disclosed
US-6645990-B2 For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases AMGEN INC. 2003-11-11 US disclosed
WO-2003070727-A1 THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2003-08-28 WO disclosed
US-20020193405-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2002-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193405-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX PRMT5 1007/4885KDM1A 2930/4885PDE8B 2863/4885
US-20040039029-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX PRMT5 1007/4885KDM1A 2930/4885PDE8B 2863/4885
US-20040044044-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX PRMT5 1007/4885KDM1A 2930/4885PDE8B 2863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.